Navigation Links
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Date:9/4/2007

dies of NGX-4010.

Dr. Jeffrey Tobias, Chief Medical Officer, commented, "We believe that NGX-4010 has the potential to provide an important therapeutic alternative to patients suffering from postherpetic neuralgia, a frequent, yet difficult to manage, neuropathic pain condition that can affect up to one in five shingles patients. We believe that a significant unmet medical need exists in the treatment of PHN, and that the results from this trial mark a significant step in our goal of providing an effective, peripherally-acting treatment option for this patient population."

Anthony DiTonno, Chief Executive Officer, said, "We believe that the results from this study are a significant validation of our efforts to develop our lead product candidate, NGX-4010, and for NeurogesX. These results represent a key milestone in our NGX-4010 development program. We feel that the consistency of both the magnitude and duration of effect of NGX-4010 is evidence of the potential benefits of this product candidate. With over 1,500 patients in our PHN and painful HIV-distal sensory polyneuropathy (HIV-DSP) clinical studies to date, we believe that we are building a significant body of evidence in support of a potential new drug application (NDA) filing in the second half of 2008."

NGX-4010 is a dermal patch designed to manage peripheral neuropathic pain. This is the second of two successful Phase 3 clinical trials of NGX-4010 for PHN that the Company has completed in the past year. The previously completed Phase 3 trial also demonstrated that a single, 60-minute treatment with NGX- 4010 applied directly to the site of pain may provide pain relief for up to 12 weeks.

In addition to being studied in PHN, NGX-4010 was also studied in a successful Phase 3 clinical trial in painful HIV-DSP and is currently being studied in a second Phase 3 trial for this indication which is currently in excess of 90% enrolled. Top-line results from this ongoing trial are expected in
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 29, 2015 ... (Troitsk) und Strand Life Sciences, weltweiter Marktführer ... Medizin, haben eine Kooperationsvereinbarung unterzeichnet. Laut Vereinbarung ... entwickeln, basierend auf NGS (Next-Generation Sequencing), für ... Formen von Epilepsie und primären Immundefizenz (PI)-Erkrankungen. ...
(Date:6/29/2015)... N.Y. and EWING, N.J. ...  (Nasdaq: CPXX ) today announced that The Leukemia ... a portion of the final payment linked to the ... lead product candidate, for the treatment of patients with ... moved forward payment of $400,000 originally attached to the ...
(Date:6/29/2015)... MOSCOW , June 29, 2015 /PRNewswire/ ... nanocenter TECHNOSPARK (Troitsk), and Strand Life Sciences, the ... personalized medicine, have signed a cooperation memorandum. According ... develop affordable tests based on next-generation sequencing (NGS) ... hereditary forms of epilepsy and primary immunodeficiency disorders ...
Breaking Medicine Technology:Das Genomic Center of Nanocenters 'Technospark' und 'Dubna', Russland und Strand Life Sciences, Indien werden gemeinsam Tests zur Diagnose von Erbkrankheiten entwickeln 2Das Genomic Center of Nanocenters 'Technospark' und 'Dubna', Russland und Strand Life Sciences, Indien werden gemeinsam Tests zur Diagnose von Erbkrankheiten entwickeln 3The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 2The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 3The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 4The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 5The Leukemia & Lymphoma Society Accelerates Milestone Payment Associated with the Phase 3 Study of CPX-351 in High Risk (Secondary) AML 6The Genomic Center of Nanocenters 'Technospark' and 'Dubna', Russia and Strand Life Sciences, India to Co-develop Tests for Diagnosis of Inherited Diseases 2The Genomic Center of Nanocenters 'Technospark' and 'Dubna', Russia and Strand Life Sciences, India to Co-develop Tests for Diagnosis of Inherited Diseases 3
(Date:6/30/2015)... ... 30, 2015 , ... Medflow, the leader in the ophthalmic ... records system from the company exclusively dedicated to helping eye care professionals for ... state-of-the-art solution combining modern cloud technology with Medflow’s proven expertise in the eye ...
(Date:6/30/2015)... ... June 30, 2015 , ... “It is never too ... SunGrubbies.com. “We are particularly interested in getting the word out to children because ... surface. We are extremely pleased with our new video which we feel ...
(Date:6/29/2015)... ... June 30, 2015 , ... The United States ... Team (KORT) as it becomes the Official Physical and Occupational Therapists of the U.S. ... Rolex Kentucky Three-Day Event presented by Land Rover. , “The USEF is pleased ...
(Date:6/29/2015)... ... June 29, 2015 , ... An upcoming documentary for public ... Earl Jones will offer a fresh perspective on conflict in sports with guest ... one of several thought leaders from around the sports industry that will discuss challenges ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one of Southern ... their newest FAA-certified medical examiner in the city of Colton . , ... seeking to obtain their physical aviation certificates. Pilots hoping to navigate airplanes, helicopters, ...
Breaking Medicine News(10 mins):Health News:Medflow Launches MEDFLOW 2.0 EHR – The Cloud-Based Ophthalmology EHR 2Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Joins Effort to Promote Sun Safety 2Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Joins Effort to Promote Sun Safety 3Health News:KORT Physical Therapy Announces Partnership with The United States Equestrian Federation 2Health News:Dr. Marc Williams Joins SCI and In America Sports Documentary 2Health News:Dr. Marc Williams Joins SCI and In America Sports Documentary 3Health News:Healthpointe Now Offering FAA Physical Exams in San Bernardino County 2
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Feb. ... called GAD-alum to treat type 1 diabetes failed to show ... sugar disease. The researchers, however, said they felt there ... and that specific groups of people still might benefit from ...
... Feb. 2 (HealthDay News) -- ,Greater use of certain types ... explain why black children,s risk of ischemic stroke dropped significantly ... in stroke-related deaths between black and white children also fell ... 74 percent more likely to die of ischemic stroke than ...
... By Alan Mozes HealthDay Reporter , THURSDAY, ... are exposed to might play a part in determining your ... about how sun may be bad for us, in terms ... an associate professor of biostatistics at the University of Alabama ...
... is associated with a loss of alcohol,s protective effect against ... increase of coronary risk among binge drinkers. ... the Danish National Cohort Study in 1994, 2000, and 2005 ... of IHD or all-cause mortality among "light-to-moderate" drinkers: (up to ...
... Mayo Clinic researchers have found that multiple exposures to ... rates of attention-deficit/hyperactivity disorder (ADHD) . Children exposed ... than double the incidence of ADHD than children who had ... Clinic pediatric anesthesiologist and investigator on the observational study. ...
... , WEDNESDAY, Feb. 1 (HealthDay News) -- ... good, it reduces inflammation in muscles at the cellular ... promote the growth of new mitochondria in skeletal muscle. ... the Buck Institute for Research on Aging and McMaster ...
Cached Medicine News:Health News:Type 1 Diabetes Treatment Disappoints in Trial 2Health News:Type 1 Diabetes Treatment Disappoints in Trial 3Health News:Efforts to Reduce Stroke in Kids With Sickle Cell Working: Study 2Health News:Lack of Sunlight May Raise Stroke Risk 2Health News:The effect of occasional binge drinking on heart disease and mortality among moderate drinkers 2Health News:Young children exposed to anesthesia multiple times show elevated rates of ADHD 2Health News:Science Shows How Massage Eases Sore Muscles 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: